Immune Checkpoint Inhibitors-induced Myasthenia Gravis: From Diagnosis to Treatment

Abstract

Immune checkpoint inhibitor (ICI) has been proven to be a major breakthrough in the treatment of various tumor types. Despite the favorable results in terms of oncological outcomes, these treatments have been associated with a variety of immune-related adverse events (irAEs). Myasthenia gravis (MG) is one of rare but life-threatening irAEs, with acute onset and rapid progression after ICI initiation. Early diagnosis and active treatment are crucial. Herein, we review recent literatures to provide guidance to frequently asked questions concerning the diagnosis and management of ICI-MG.

Keywords

• immune checkpoint inhibitor
• myasthenia gravis
• peripheral neuropathy
• immune-related adverse events